Advertisement

Index by Author

February 2000; 23 (2)
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z

A

  1. Abbasi, F

    • Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care February 2000 23:171-175; doi:10.2337/diacare.23.2.171

  2. Aldasouqi, S A

    • The Batista procedure significantly improved cardiac function and glycemic control in a diabetic patient with severe insulin resistance. Diabetes Care February 2000 23:255-256; doi:10.2337/diacare.23.2.255

  3. Andersen, S J

    • Contribution of abnormalities of thyroid hormones to type 2 diabetes. Diabetes Care February 2000 23:260-261; doi:10.2337/diacare.23.2.260a

  4. Anderson, C M

    • Lamin A/C mutation in a woman and her two daughters with Dunnigan-type partial lipodystrophy and insulin resistance. Diabetes Care February 2000 23:258-259; doi:10.2337/diacare.23.2.258

  5. Armstrong, D

    • Serum markers of oxidative stress and severity of diabetic retinopathy. Diabetes Care February 2000 23:234-240; doi:10.2337/diacare.23.2.234

  6. Asaka, M

    • Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes. Diabetes Care February 2000 23:256-258; doi:10.2337/diacare.23.2.256

B

  1. Belch, J J

    • Impaired skin microvascular function in children, adolescents, and young adults with type 1 diabetes. Diabetes Care February 2000 23:215-220; doi:10.2337/diacare.23.2.215

  2. Bloomgarden, Z T

    • American Diabetes Association Annual Meeting, 1999: insulin action and the development of type 2 diabetes. Diabetes Care February 2000 23:248-252; doi:10.2337/diacare.23.2.248

  3. Bouter, K P

    • Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care February 2000 23:202-207; doi:10.2337/diacare.23.2.202

  4. Bouter, L M

    • Major stressful life events in relation to prevalence of undetected type 2 diabetes: the Hoorn Study. Diabetes Care February 2000 23:197-201; doi:10.2337/diacare.23.2.197

  5. Boyko, E J

    • Reassessing the role of QTc in the diagnosis of autonomic failure among patients with diabetes: a meta-analysis. Diabetes Care February 2000 23:241-247; doi:10.2337/diacare.23.2.241

  6. Brock, D B

    • American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. Diabetes Care February 2000 23:176-180; doi:10.2337/diacare.23.2.176

  7. Browne, R W

    • Serum markers of oxidative stress and severity of diabetic retinopathy. Diabetes Care February 2000 23:234-240; doi:10.2337/diacare.23.2.234

C

  1. Cao, H

    • Lamin A/C mutation in a woman and her two daughters with Dunnigan-type partial lipodystrophy and insulin resistance. Diabetes Care February 2000 23:258-259; doi:10.2337/diacare.23.2.258

  2. Carantoni, M

    • Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care February 2000 23:171-175; doi:10.2337/diacare.23.2.171

  3. Clarke, W L

    • Progressive hypoglycemia's impact on driving simulation performance. Occurrence, awareness and correction. Diabetes Care February 2000 23:163-170; doi:10.2337/diacare.23.2.163

  4. Contreras, R

    • Evaluation of the effect of performance monitoring and feedback on care process, utilization, and outcome. Diabetes Care February 2000 23:192-196; doi:10.2337/diacare.23.2.192

  5. Cox, D J

    • Progressive hypoglycemia's impact on driving simulation performance. Occurrence, awareness and correction. Diabetes Care February 2000 23:163-170; doi:10.2337/diacare.23.2.163

D

  1. De Mattia, G

    • Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality. Diabetes Care February 2000 23:228-233; doi:10.2337/diacare.23.2.228

  2. Deng, Y J

    • Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality. Diabetes Care February 2000 23:228-233; doi:10.2337/diacare.23.2.228

  3. Derobert, E

    • Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care February 2000 23:157-162; doi:10.2337/diacare.23.2.157

  4. de Vries, H

    • Major stressful life events in relation to prevalence of undetected type 2 diabetes: the Hoorn Study. Diabetes Care February 2000 23:197-201; doi:10.2337/diacare.23.2.197

  5. Dickinson, S

    • Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care February 2000 23:202-207; doi:10.2337/diacare.23.2.202

  6. Doi, K

    • Effect of bezafibrate on insulin sensitivity in nonobese Japanese type 2 diabetic patients. Diabetes Care February 2000 23:259; doi:10.2337/diacare.23.2.259

  7. Domurat, E S

    • Evaluation of the effect of performance monitoring and feedback on care process, utilization, and outcome. Diabetes Care February 2000 23:192-196; doi:10.2337/diacare.23.2.192

  8. Dudl, J

    • Evaluation of the effect of performance monitoring and feedback on care process, utilization, and outcome. Diabetes Care February 2000 23:192-196; doi:10.2337/diacare.23.2.192

E

  1. Eberhardt, M S

    • Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care February 2000 23:187-191; doi:10.2337/diacare.23.2.187

  2. Edelman, S

    • Hypoglycemia and driving performance: a flashing yellow light? Diabetes Care February 2000 23:146-147; doi:10.2337/diacare.23.2.146

  3. Eisenbarth, G S

    • Isotypes of anti-islet autoantibodies. Diabetes Care February 2000 23:151-152; doi:10.2337/diacare.23.2.151

  4. Elbein, S C

    • Reduced beta-cell compensation to the insulin resistance associated with obesity in members of caucasian familial type 2 diabetic kindreds. Diabetes Care February 2000 23:221-227; doi:10.2337/diacare.23.2.221

  5. Elhadd, T A

    • Impaired skin microvascular function in children, adolescents, and young adults with type 1 diabetes. Diabetes Care February 2000 23:215-220; doi:10.2337/diacare.23.2.215

  6. England, J D

    • Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care February 2000 23:187-191; doi:10.2337/diacare.23.2.187

  7. Eto, T

    • Plasma adrenomedullin levels in patients with diabetes. Diabetes Care February 2000 23:253-254; doi:10.2337/diacare.23.2.253

  8. Eugène-Jolchine, I

    • Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care February 2000 23:157-162; doi:10.2337/diacare.23.2.157

F

  1. Fabsitz, R R

    • Prevalence of undiagnosed diabetes in three American Indian populations. A comparison of the 1997 American Diabetes Association diagnostic criteria and the 1985 World Health Organization diagnostic criteria: the Strong Heart Study. Diabetes Care February 2000 23:181-186; doi:10.2337/diacare.23.2.181

  2. Fava, D

    • Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality. Diabetes Care February 2000 23:228-233; doi:10.2337/diacare.23.2.228

  3. Flegal, K M

    • Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care February 2000 23:187-191; doi:10.2337/diacare.23.2.187

  4. Frier, B M

    • Hypoglycemia and driving performance. Diabetes Care February 2000 23:148-150; doi:10.2337/diacare.23.2.148

  5. Fujimoto, S

    • Plasma adrenomedullin levels in patients with diabetes. Diabetes Care February 2000 23:253-254; doi:10.2337/diacare.23.2.253

  6. Fujita, T

    • MTHFR gene polymorphism as an exacerbation factor of diabetic nephropathy in type 2 diabetes. Analysis in Japanese male hemodialysis patients. Diabetes Care February 2000 23:260; doi:10.2337/diacare.23.2.260b

  7. Fukushima, M

    • Effect of bezafibrate on insulin sensitivity in nonobese Japanese type 2 diabetic patients. Diabetes Care February 2000 23:259; doi:10.2337/diacare.23.2.259

G

  1. Gamble, G D

    • Can medication packaging improve glycemic control and blood pressure in type 2 diabetes? Results from a randomized controlled trial. Diabetes Care February 2000 23:153-156; doi:10.2337/diacare.23.2.153

  2. Gerritsen, M

    • Problems associated with subcutaneously implanted glucose sensors. Diabetes Care February 2000 23:143-145; doi:10.2337/diacare.23.2.143

  3. Gilligan, B J

    • A subcutaneous glucose sensor with improved longevity, dynamic range, and stability of calibration. Diabetes Care February 2000 23:208-214; doi:10.2337/diacare.23.2.208

  4. Goldstein, D E

    • Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care February 2000 23:187-191; doi:10.2337/diacare.23.2.187

  5. Gonder-Frederick, L A

    • Progressive hypoglycemia's impact on driving simulation performance. Occurrence, awareness and correction. Diabetes Care February 2000 23:163-170; doi:10.2337/diacare.23.2.163

  6. Go, O

    • Prevalence of undiagnosed diabetes in three American Indian populations. A comparison of the 1997 American Diabetes Association diagnostic criteria and the 1985 World Health Organization diagnostic criteria: the Strong Heart Study. Diabetes Care February 2000 23:181-186; doi:10.2337/diacare.23.2.181

  7. Greene, S A

    • Impaired skin microvascular function in children, adolescents, and young adults with type 1 diabetes. Diabetes Care February 2000 23:215-220; doi:10.2337/diacare.23.2.215

  8. Grootenhuis, P A

    • Major stressful life events in relation to prevalence of undetected type 2 diabetes: the Hoorn Study. Diabetes Care February 2000 23:197-201; doi:10.2337/diacare.23.2.197

  9. Guitard, C

    • Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care February 2000 23:202-207; doi:10.2337/diacare.23.2.202

H

  1. Hanefeld, M

    • Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care February 2000 23:202-207; doi:10.2337/diacare.23.2.202

  2. Harris, M I

    • American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. Diabetes Care February 2000 23:176-180; doi:10.2337/diacare.23.2.176
    • Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care February 2000 23:187-191; doi:10.2337/diacare.23.2.187

  3. Harris, T B

    • American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. Diabetes Care February 2000 23:176-180; doi:10.2337/diacare.23.2.176

  4. Hartnett, M E

    • Serum markers of oxidative stress and severity of diabetic retinopathy. Diabetes Care February 2000 23:234-240; doi:10.2337/diacare.23.2.234

  5. Hawa, M I

    • Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality. Diabetes Care February 2000 23:228-233; doi:10.2337/diacare.23.2.228

  6. Hegele, R A

    • Lamin A/C mutation in a woman and her two daughters with Dunnigan-type partial lipodystrophy and insulin resistance. Diabetes Care February 2000 23:258-259; doi:10.2337/diacare.23.2.258

  7. Heine, R J

    • Major stressful life events in relation to prevalence of undetected type 2 diabetes: the Hoorn Study. Diabetes Care February 2000 23:197-201; doi:10.2337/diacare.23.2.197

  8. Hisanaga, S

    • Plasma adrenomedullin levels in patients with diabetes. Diabetes Care February 2000 23:253-254; doi:10.2337/diacare.23.2.253

  9. Howard, B V

    • Prevalence of undiagnosed diabetes in three American Indian populations. A comparison of the 1997 American Diabetes Association diagnostic criteria and the 1985 World Health Organization diagnostic criteria: the Strong Heart Study. Diabetes Care February 2000 23:181-186; doi:10.2337/diacare.23.2.181

  10. Hyatt, J A

    • Evaluation of the effect of performance monitoring and feedback on care process, utilization, and outcome. Diabetes Care February 2000 23:192-196; doi:10.2337/diacare.23.2.192

I

  1. Imamura, M

    • Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes. Diabetes Care February 2000 23:256-258; doi:10.2337/diacare.23.2.256

J

  1. Julian, D M

    • Progressive hypoglycemia's impact on driving simulation performance. Occurrence, awareness and correction. Diabetes Care February 2000 23:163-170; doi:10.2337/diacare.23.2.163

K

  1. Kahn, S E

    • Reduced beta-cell compensation to the insulin resistance associated with obesity in members of caucasian familial type 2 diabetic kindreds. Diabetes Care February 2000 23:221-227; doi:10.2337/diacare.23.2.221

  2. Kato, K

    • Plasma adrenomedullin levels in patients with diabetes. Diabetes Care February 2000 23:253-254; doi:10.2337/diacare.23.2.253

  3. Khan, F

    • Impaired skin microvascular function in children, adolescents, and young adults with type 1 diabetes. Diabetes Care February 2000 23:215-220; doi:10.2337/diacare.23.2.215

  4. Khokher, M A

    • Differential antioxidant status among Indo-Asians compared with caucasians with and without diabetes. Wolverhampton Diabetes Research Group. Diabetes Care February 2000 23:254-255; doi:10.2337/diacare.23.2.254

  5. Kim, S R

    • Contribution of abnormalities of thyroid hormones to type 2 diabetes. Diabetes Care February 2000 23:260-261; doi:10.2337/diacare.23.2.260a

  6. Kinoshita, H

    • Plasma adrenomedullin levels in patients with diabetes. Diabetes Care February 2000 23:253-254; doi:10.2337/diacare.23.2.253

  7. Kitamura, K

    • Plasma adrenomedullin levels in patients with diabetes. Diabetes Care February 2000 23:253-254; doi:10.2337/diacare.23.2.253

  8. Kovatchev, B P

    • Progressive hypoglycemia's impact on driving simulation performance. Occurrence, awareness and correction. Diabetes Care February 2000 23:163-170; doi:10.2337/diacare.23.2.163

  9. Kuller, L H

    • Contribution of abnormalities of thyroid hormones to type 2 diabetes. Diabetes Care February 2000 23:260-261; doi:10.2337/diacare.23.2.260a

  10. Kumagai, M

    • Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes. Diabetes Care February 2000 23:256-258; doi:10.2337/diacare.23.2.256

  11. Kuroki, M

    • Plasma adrenomedullin levels in patients with diabetes. Diabetes Care February 2000 23:253-254; doi:10.2337/diacare.23.2.253

L

  1. Lanham, R J

    • Serum markers of oxidative stress and severity of diabetic retinopathy. Diabetes Care February 2000 23:234-240; doi:10.2337/diacare.23.2.234

  2. Lee, E T

    • Prevalence of undiagnosed diabetes in three American Indian populations. A comparison of the 1997 American Diabetes Association diagnostic criteria and the 1985 World Health Organization diagnostic criteria: the Strong Heart Study. Diabetes Care February 2000 23:181-186; doi:10.2337/diacare.23.2.181

  3. Leslie, R D

    • Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality. Diabetes Care February 2000 23:228-233; doi:10.2337/diacare.23.2.228

  4. Little, R R

    • Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care February 2000 23:187-191; doi:10.2337/diacare.23.2.187

  5. Logue, W J

    • The Batista procedure significantly improved cardiac function and glycemic control in a diabetic patient with severe insulin resistance. Diabetes Care February 2000 23:255-256; doi:10.2337/diacare.23.2.255

M

  1. Madsen, R

    • Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care February 2000 23:187-191; doi:10.2337/diacare.23.2.187

  2. Marrero, D

    • Hypoglycemia and driving performance: a flashing yellow light? Diabetes Care February 2000 23:146-147; doi:10.2337/diacare.23.2.146

  3. Medici, F

    • Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality. Diabetes Care February 2000 23:228-233; doi:10.2337/diacare.23.2.228

  4. Mizue, Y

    • Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes. Diabetes Care February 2000 23:256-258; doi:10.2337/diacare.23.2.256

  5. Mooy, J M

    • Major stressful life events in relation to prevalence of undetected type 2 diabetes: the Hoorn Study. Diabetes Care February 2000 23:197-201; doi:10.2337/diacare.23.2.197

N

  1. Nagasaka, S

    • Effect of bezafibrate on insulin sensitivity in nonobese Japanese type 2 diabetic patients. Diabetes Care February 2000 23:259; doi:10.2337/diacare.23.2.259

  2. Nagata, I

    • Effect of bezafibrate on insulin sensitivity in nonobese Japanese type 2 diabetic patients. Diabetes Care February 2000 23:259; doi:10.2337/diacare.23.2.259

  3. Nakai, Y

    • Effect of bezafibrate on insulin sensitivity in nonobese Japanese type 2 diabetic patients. Diabetes Care February 2000 23:259; doi:10.2337/diacare.23.2.259

  4. Nakamura, S

    • Plasma adrenomedullin levels in patients with diabetes. Diabetes Care February 2000 23:253-254; doi:10.2337/diacare.23.2.253

  5. Nakao, A

    • MTHFR gene polymorphism as an exacerbation factor of diabetic nephropathy in type 2 diabetes. Analysis in Japanese male hemodialysis patients. Diabetes Care February 2000 23:260; doi:10.2337/diacare.23.2.260b

  6. Nishihira, J

    • Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes. Diabetes Care February 2000 23:256-258; doi:10.2337/diacare.23.2.256

  7. Noiri, E

    • MTHFR gene polymorphism as an exacerbation factor of diabetic nephropathy in type 2 diabetes. Analysis in Japanese male hemodialysis patients. Diabetes Care February 2000 23:260; doi:10.2337/diacare.23.2.260b

  8. Notkins, A L

    • Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality. Diabetes Care February 2000 23:228-233; doi:10.2337/diacare.23.2.228

O

  1. Ohtsuka, Y

    • Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes. Diabetes Care February 2000 23:256-258; doi:10.2337/diacare.23.2.256

P

  1. Petitti, D B

    • Evaluation of the effect of performance monitoring and feedback on care process, utilization, and outcome. Diabetes Care February 2000 23:192-196; doi:10.2337/diacare.23.2.192

  2. Pieber, T R

    • Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care February 2000 23:157-162; doi:10.2337/diacare.23.2.157

R

  1. Rea, C A

    • Differential antioxidant status among Indo-Asians compared with caucasians with and without diabetes. Wolverhampton Diabetes Research Group. Diabetes Care February 2000 23:254-255; doi:10.2337/diacare.23.2.254

  2. Reaven, G M

    • Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care February 2000 23:171-175; doi:10.2337/diacare.23.2.171

  3. Resnick, H E

    • American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. Diabetes Care February 2000 23:176-180; doi:10.2337/diacare.23.2.176

  4. Rhodes, R K

    • A subcutaneous glucose sensor with improved longevity, dynamic range, and stability of calibration. Diabetes Care February 2000 23:208-214; doi:10.2337/diacare.23.2.208

  5. Robbins, D C

    • Prevalence of undiagnosed diabetes in three American Indian populations. A comparison of the 1997 American Diabetes Association diagnostic criteria and the 1985 World Health Organization diagnostic criteria: the Strong Heart Study. Diabetes Care February 2000 23:181-186; doi:10.2337/diacare.23.2.181

  6. Rohlfing, C L

    • Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care February 2000 23:187-191; doi:10.2337/diacare.23.2.187

  7. Rosner, B A

    • Serum markers of oxidative stress and severity of diabetic retinopathy. Diabetes Care February 2000 23:234-240; doi:10.2337/diacare.23.2.234

S

  1. Sahni, A

    • Differential antioxidant status among Indo-Asians compared with caucasians with and without diabetes. Wolverhampton Diabetes Research Group. Diabetes Care February 2000 23:254-255; doi:10.2337/diacare.23.2.254

  2. Sakai, M

    • Effect of bezafibrate on insulin sensitivity in nonobese Japanese type 2 diabetic patients. Diabetes Care February 2000 23:259; doi:10.2337/diacare.23.2.259

  3. Savage, P J

    • Prevalence of undiagnosed diabetes in three American Indian populations. A comparison of the 1997 American Diabetes Association diagnostic criteria and the 1985 World Health Organization diagnostic criteria: the Strong Heart Study. Diabetes Care February 2000 23:181-186; doi:10.2337/diacare.23.2.181

  4. Shults, M C

    • A subcutaneous glucose sensor with improved longevity, dynamic range, and stability of calibration. Diabetes Care February 2000 23:208-214; doi:10.2337/diacare.23.2.208

  5. Simmons, D

    • Can medication packaging improve glycemic control and blood pressure in type 2 diabetes? Results from a randomized controlled trial. Diabetes Care February 2000 23:153-156; doi:10.2337/diacare.23.2.153

  6. Singh, B M

    • Differential antioxidant status among Indo-Asians compared with caucasians with and without diabetes. Wolverhampton Diabetes Research Group. Diabetes Care February 2000 23:254-255; doi:10.2337/diacare.23.2.254

  7. Siscovick, D S

    • Reassessing the role of QTc in the diagnosis of autonomic failure among patients with diabetes: a meta-analysis. Diabetes Care February 2000 23:241-247; doi:10.2337/diacare.23.2.241

  8. Stratton, R D

    • Serum markers of oxidative stress and severity of diabetic retinopathy. Diabetes Care February 2000 23:234-240; doi:10.2337/diacare.23.2.234

T

  1. Taguchi, J

    • MTHFR gene polymorphism as an exacerbation factor of diabetic nephropathy in type 2 diabetes. Analysis in Japanese male hemodialysis patients. Diabetes Care February 2000 23:260; doi:10.2337/diacare.23.2.260b

  2. Talbott, E A

    • Contribution of abnormalities of thyroid hormones to type 2 diabetes. Diabetes Care February 2000 23:260-261; doi:10.2337/diacare.23.2.260a

  3. Taniguchi, A

    • Effect of bezafibrate on insulin sensitivity in nonobese Japanese type 2 diabetic patients. Diabetes Care February 2000 23:259; doi:10.2337/diacare.23.2.259

  4. Tokuyama, K

    • Effect of bezafibrate on insulin sensitivity in nonobese Japanese type 2 diabetic patients. Diabetes Care February 2000 23:259; doi:10.2337/diacare.23.2.259

  5. Tsuji, M

    • Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes. Diabetes Care February 2000 23:256-258; doi:10.2337/diacare.23.2.256

  6. Tull, E

    • Contribution of abnormalities of thyroid hormones to type 2 diabetes. Diabetes Care February 2000 23:260-261; doi:10.2337/diacare.23.2.260a

U

  1. Updike, S J

    • A subcutaneous glucose sensor with improved longevity, dynamic range, and stability of calibration. Diabetes Care February 2000 23:208-214; doi:10.2337/diacare.23.2.208

  2. Upjohn, M

    • Can medication packaging improve glycemic control and blood pressure in type 2 diabetes? Results from a randomized controlled trial. Diabetes Care February 2000 23:153-156; doi:10.2337/diacare.23.2.153

V

  1. Vogt, M

    • Contribution of abnormalities of thyroid hormones to type 2 diabetes. Diabetes Care February 2000 23:260-261; doi:10.2337/diacare.23.2.260a

W

  1. Wegner, K

    • Reduced beta-cell compensation to the insulin resistance associated with obesity in members of caucasian familial type 2 diabetic kindreds. Diabetes Care February 2000 23:221-227; doi:10.2337/diacare.23.2.221

  2. Welty, T K

    • Prevalence of undiagnosed diabetes in three American Indian populations. A comparison of the 1997 American Diabetes Association diagnostic criteria and the 1985 World Health Organization diagnostic criteria: the Strong Heart Study. Diabetes Care February 2000 23:181-186; doi:10.2337/diacare.23.2.181

  3. Wen, Y

    • Differential antioxidant status among Indo-Asians compared with caucasians with and without diabetes. Wolverhampton Diabetes Research Group. Diabetes Care February 2000 23:254-255; doi:10.2337/diacare.23.2.254

  4. Whitsel, E A

    • Reassessing the role of QTc in the diagnosis of autonomic failure among patients with diabetes: a meta-analysis. Diabetes Care February 2000 23:241-247; doi:10.2337/diacare.23.2.241

  5. Wiedmeyer, H M

    • Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care February 2000 23:187-191; doi:10.2337/diacare.23.2.187

Y

  1. Yabunaka, N

    • Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes. Diabetes Care February 2000 23:256-258; doi:10.2337/diacare.23.2.256

  2. Yeni-Komshian, H

    • Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care February 2000 23:171-175; doi:10.2337/diacare.23.2.171

Z

  1. Zhang, X H

    • Differential antioxidant status among Indo-Asians compared with caucasians with and without diabetes. Wolverhampton Diabetes Research Group. Diabetes Care February 2000 23:254-255; doi:10.2337/diacare.23.2.254

  2. Ziel, F H

    • Evaluation of the effect of performance monitoring and feedback on care process, utilization, and outcome. Diabetes Care February 2000 23:192-196; doi:10.2337/diacare.23.2.192

Current Issue

  1. February 2012, 35 (2)
  1. Current Issue
  1. Alert me to new issues of Diabetes Care
Advertisement